Identifying Optimal Candidates for Local Treatment of the Primary Tumor Among Patients Diagnosed with Metastatic Prostate Cancer: A SEER-based Study

Heidenreich, 2014, EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer, Eur Urol, 65, 467, 10.1016/j.eururo.2013.11.002 Culp, 2014, Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study, Eur Urol, 65, 1058, 10.1016/j.eururo.2013.11.012 Flanigan, 2001, Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer, N Engl J Med, 345, 1655, 10.1056/NEJMoa003013 Temple, 2004, Use of surgery among elderly patients with stage IV colorectal cancer, J Clin Oncol, 22, 3475, 10.1200/JCO.2004.10.218 Kaplan, 2005, VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche, Nature, 438, 820, 10.1038/nature04186 Psaila, 2009, The metastatic niche: adapting the foreign soil, Nat Rev Cancer, 9, 285, 10.1038/nrc2621 Kantoff, 2010, Sipuleucel-T Immunotherapy for castration-resistant prostate cancer, N Engl J Med, 363, 411, 10.1056/NEJMoa1001294 de Bono, 2011, Abiraterone and increased survival in metastatic prostate cancer, N Engl J Med, 364, 1995, 10.1056/NEJMoa1014618 James, 2012, Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial, Lancet Oncol, 13, 549, 10.1016/S1470-2045(12)70088-8